NasdaqCM:SLSBiotechs
Is SELLAS Life Sciences Group (SLS) Fully Priced As Regal Trial Debate Heats Up?
SELLAS Life Sciences Group (SLS) stock is back in focus after CEO Angelos Stergiou said the Regal Phase 3 trial is nearing its 80 event trigger, while Martin Shkreli’s public critique added pressure and uncertainty.
See our latest analysis for SELLAS Life Sciences Group.
The recent commentary around the Regal trial has arrived against a backdrop of strong momentum in SELLAS Life Sciences Group’s stock, with a 30 day share price return of 36.05% and a 90 day share price return of 176.68%. The...